Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2025-12-25 @ 1:46 AM
NCT ID:
NCT05676294
Eligibility Criteria:
Inclusion Criteria:
* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Female aged 18-50
* Scheduled to undergo ambulatory surgery under general anesthesia
* Access to smartphone device or computer with internet connection and has an email address
Exclusion Criteria:
* Non-English speaking
* Unable to swallow pills
* Current use of anti-psychotic medications
* History of allergy to olanzapine
* Pregnancy/Lactation
* Current use of antihypertensive medication
* Diabetes Mellitus
* Clinically significant cardiovascular disease defined as follows:
1. Myocardial infarction or unstable angina within 6 months prior to the day of planned surgery.
2. History of serious ventricular arrhythmia (i.e.: ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled on anti-arrhythmic medication.
3. New York Heart Association Class II or higher congestive heart failure.
4. Postural hypotension or vasovagal syncope within 6 months of planned surgery.
* Hypotension on day of surgery, defined as a systolic blood pressure \< 90mmHg
* Seizure disorder
* Clinically active prolactinoma
* Hepatic disease
* Narrow angle glaucoma
* Parkinson's disease
* Lewy body dementia
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT05676294
Study Brief:
Protocol Section:
NCT05676294